Genmab A/SGenmab A/SGenmab A/S

Genmab A/S

No trades
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪18.37 B‬USD
25.06USD
‪1.09 B‬USD
‪2.98 B‬USD
‪58.40 M‬
Beta (1Y)
0.59
Employees (FY)
‪2.68 K‬
Change (1Y)
+478 +21.69%
Revenue / Employee (1Y)
‪1.11 M‬USD
Net income / Employee (1Y)
‪404.78 K‬USD

About Genmab A/S


CEO
Jan G. J. van de Winkel
Website
Headquarters
Copenhagen
Founded
1998
IPO date
Oct 1, 2000
Identifiers
2
ISIN DK0010272202
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Check out other big names from the same industry as GNMSF.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
GMXAY6238867
Genmab A/S 7.25% 15-DEC-2033
Yield to maturity
6.43%
Maturity date
Dec 15, 2033
GMXAY6238865
Genmab A/S 6.25% 15-DEC-2032
Yield to maturity
5.76%
Maturity date
Dec 15, 2032

See all GNMSF bonds 

VXUS
Vanguard Total International Stock ETF
Weight
0.05%
Market value
‪279.49 M‬
USD
VEA
Vanguard FTSE Developed Markets ETF
Weight
0.07%
Market value
‪180.51 M‬
USD
IEFA
iShares Core MSCI EAFE ETF
Weight
0.07%
Market value
‪127.38 M‬
USD
EFA
iShares MSCI EAFE ETF
Weight
0.08%
Market value
‪64.09 M‬
USD
XACTC25
XACT OMXC25 ESG (UCITS ETF)
Weight
6.10%
Market value
‪54.23 M‬
USD
VGK
Vanguard FTSEEuropean ETF
Weight
0.13%
Market value
‪47.24 M‬
USD
VEU
Vanguard FTSE All World Ex US ETF
Weight
0.05%
Market value
‪41.77 M‬
USD
SCHF
Schwab International Equity ETF
Weight
0.07%
Market value
‪39.73 M‬
USD
IWDG
iShares Core MSCI World UCITS ETF Hedged GBP
Weight
0.02%
Market value
‪32.51 M‬
USD
SWDA
iShares Core MSCI World UCITS ETF
Weight
0.02%
Market value
‪32.51 M‬
USD
IWDD
iShares III PLC - iShares Core MSCI World UCITS ETF USD
Weight
0.02%
Market value
‪32.51 M‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of GNMSF is 300.00 USD — it has decreased by −2.60% in the past 24 hours. Watch Genmab A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Genmab A/S stocks are traded under the ticker GNMSF.
GNMSF stock has fallen by −9.26% compared to the previous week, the month change is a −10.34% fall, over the last year Genmab A/S has showed a 57.51% increase.
We've gathered analysts' opinions on Genmab A/S future price: according to them, GNMSF price has a max estimate of 480.00 USD and a min estimate of 204.94 USD. Watch GNMSF chart and read a more detailed Genmab A/S stock forecast: see what analysts think of Genmab A/S and suggest that you do with its stocks.
GNMSF reached its all-time high on Sep 2, 2021 with the price of 500.92 USD, and its all-time low was 3.30 USD and was reached on Dec 3, 2009. View more price dynamics on GNMSF chart.
See other stocks reaching their highest and lowest prices.
GNMSF stock is 2.67% volatile and has beta coefficient of 0.59. Track Genmab A/S stock price on the chart and check out the list of the most volatile stocks — is Genmab A/S there?
Today Genmab A/S has the market capitalization of ‪18.37 B‬, it has decreased by −7.19% over the last week.
Yes, you can track Genmab A/S financials in yearly and quarterly reports right on TradingView.
Genmab A/S is going to release the next earnings report on May 7, 2026. Keep track of upcoming events with our Earnings Calendar.
GNMSF earnings for the last quarter are 4.71 USD per share, whereas the estimation was 4.44 USD resulting in a 6.25% surprise. The estimated earnings for the next quarter are 2.16 USD per share. See more details about Genmab A/S earnings.
Genmab A/S revenue for the last quarter amounts to ‪1.06 B‬ USD, despite the estimated figure of ‪1.05 B‬ USD. In the next quarter, revenue is expected to reach ‪902.63 M‬ USD.
GNMSF net income for the last quarter is ‪401.57 M‬ USD, while the quarter before that showed ‪348.45 M‬ USD of net income which accounts for 15.25% change. Track more Genmab A/S financial stats to get the full picture.
No, GNMSF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 12, 2026, the company has ‪2.68 K‬ employees. See our rating of the largest employees — is Genmab A/S on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Genmab A/S EBITDA is ‪1.45 B‬ USD, and current EBITDA margin is 34.45%. See more stats in Genmab A/S financial statements.
Like other stocks, GNMSF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Genmab A/S stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Genmab A/S technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Genmab A/S stock shows the buy signal. See more of Genmab A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.